Search

Your search keyword '"Larsen, Thomas S."' showing total 155 results
Start Over Author "Larsen, Thomas S."

Refine your results

more »

more »

more »

more »
155 results on '"Larsen, Thomas S."'

1. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Author

Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell’Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie-Laure, Manzke, Oliver, and Munoz, Javier

Published
2022
Full Text
View/download PDF

2. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

Author

Husby, Simon, Favero, Francesco, Nielsen, Christian, Sørensen, Betina S., Bæch, John, Grell, Kathrine, Hansen, Jakob W., Rodriguez-Gonzalez, Francisco G., Haastrup, Eva K., Fischer-Nielsen, Anne, Andersen, Pernille, Arboe, Bente, Sækmose, Susanne G., Hansen, Per B., Christiansen, Ilse, Clasen-Linde, Erik, Meldgaard, Lene, Ebbesen, Lene H., Segel, Erik K., Josefsson, Pär, Thorsgaard, Michael, El-Galaly, Tarec C., Brown, Peter, Weischenfeldt, Joachim, Larsen, Thomas S., and Grønbæk, Kirsten

Published
2020
Full Text
View/download PDF

3. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Author

El-Galaly, Tarec Christoffer, Cheah, Chan Yoon, Bendtsen, Mette Dahl, Nowakowski, Grzegorz S., Kansara, Roopesh, Savage, Kerry J., Connors, Joseph M., Sehn, Laurie H., Goldschmidt, Neta, Shaulov, Adir, Farooq, Umar, Link, Brian K., Ferreri, Andrés J.M., Calimeri, Teresa, Cecchetti, Caterina, Dann, Eldad J., Thompson, Carrie A., Inbar, Tsofia, Maurer, Matthew J., Gade, Inger Lise, Juul, Maja Bech, Hansen, Jakob W., Holmberg, Staffan, Larsen, Thomas S., Cordua, Sabrina, Mikhaeel, N. George, Hutchings, Martin, Seymour, John F., Clausen, Michael Roost, Smith, Daniel, Opat, Stephen, Gilbertson, Michael, Thanarajasingam, Gita, and Villa, Diego

Published
2018
Full Text
View/download PDF

5. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy

Author

El-Galaly, Tarec Christoffer, Villa, Diego, Michaelsen, Thomas Yssing, Hutchings, Martin, Mikhaeel, Nabegh George, Savage, Kerry J., Sehn, Laurie H., Barrington, Sally, Hansen, Jakob W., Smith, Daniel, Rady, Kirsty, Mylam, Karen J., Larsen, Thomas S., Holmberg, Staffan, Juul, Maja B., Cordua, Sabrina, Clausen, Michael R., Jensen, Kristina B., Johnsen, Hans E., Seymour, John F., Connors, Joseph M., de Nully Brown, Peter, Bøgsted, Martin, and Cheah, Chan Y.

Published
2017
Full Text
View/download PDF

6. Reproduction patterns among non‐Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population‐based matched cohort study

Author

Entrop, Joshua P., primary, Weibull, Caroline E., additional, Smedby, Karin E., additional, Jakobsen, Lasse H., additional, Øvlisen, Andreas K., additional, Glimelius, Ingrid, additional, Marklund, Anna, additional, Larsen, Thomas S., additional, Holte, Harald, additional, Fosså, Alexander, additional, Smeland, Knut B., additional, El‐Galaly, Tarec C., additional, and Eloranta, Sandra, additional

Published
2023
Full Text
View/download PDF

8. Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway:A population-based matched cohort study

Author

Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Øvlisen, Andreas K., Glimelius, Ingrid, Marklund, Anna, Larsen, Thomas S., Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec C., and Eloranta, Sandra

Subjects
fertility, non-Hodgkin lymphoma, late effects of therapy
Abstract

Previous studies concerning reproductive patterns among non-Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. Treatment regimens vary considerably between aggressive and indolent NHL and studies of reproductive patterns by subtypes are warranted. In this matched cohort study, we identified all NHL patients aged 18–40 years and diagnosed between 2000 and 2018 from the Swedish and Danish lymphoma registers, and the clinical database at Oslo University Hospital (n = 2090). Population comparators were matched on sex, birth year and country (n = 19 427). Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggressive lymphoma subtypes had lower childbirth rates (HRfemale: 0.43, 95% CI: 0.31–0.59, HRmale: 0.61, 95% CI: 0.47–0.78) than comparators during the first 3 years after diagnosis. For indolent lymphomas, childbirth rates were not significantly different from comparators (HRfemale: 0.71, 95% CI: 0.48–1.04, HRmale: 0.94, 95% CI: 0.70–1.27) during the same period. Childbirth rates reached those of comparators for all subtypes after 3 years but the cumulative incidence of childbirths was decreased throughout the 10-year follow-up for aggressive NHL. Children of NHL patients were more likely to be born following assisted reproductive technology than those of comparators, except for male indolent lymphoma patients. In conclusion, fertility counselling is particularly important for patients with aggressive NHL.

Published
2023
Full Text
View/download PDF

9. Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Author

Knudsen, Trine A., Hansen, Dennis Lund, Ocias, Lukas Frans, Bjerrum, Ole Weis, Brabrand, Mette, Christensen, Sarah F., Eickhardt-Dalbøge, Christina Schjellerup S., Ellervik, Christina, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Larsen, Morten Kranker, Mourits-Andersen, Torben, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Sørensen, Anders Lindholm, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas S., and Hasselbalch, Hans Carl

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

10. Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway : A population-based matched cohort study

Author

Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Ovlisen, Andreas K., Glimelius, Ingrid, Marklund, Anna, Larsen, Thomas S., Holte, Harald, Fossa, Alexander, Smeland, Knut B., El-Galaly, Tarec C., Eloranta, Sandra, Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse H., Ovlisen, Andreas K., Glimelius, Ingrid, Marklund, Anna, Larsen, Thomas S., Holte, Harald, Fossa, Alexander, Smeland, Knut B., El-Galaly, Tarec C., and Eloranta, Sandra

Abstract

Previous studies concerning reproductive patterns among non-Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. Treatment regimens vary considerably between aggressive and indolent NHL and studies of reproductive patterns by subtypes are warranted. In this matched cohort study, we identified all NHL patients aged 18-40 years and diagnosed between 2000 and 2018 from the Swedish and Danish lymphoma registers, and the clinical database at Oslo University Hospital (n = 2090). Population comparators were matched on sex, birth year and country (n = 19 427). Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggressive lymphoma subtypes had lower childbirth rates (HRfemale: 0.43, 95% CI: 0.31-0.59, HRmale: 0.61, 95% CI: 0.47-0.78) than comparators during the first 3 years after diagnosis. For indolent lymphomas, childbirth rates were not significantly different from comparators (HRfemale: 0.71, 95% CI: 0.48-1.04, HRmale: 0.94, 95% CI: 0.70-1.27) during the same period. Childbirth rates reached those of comparators for all subtypes after 3 years but the cumulative incidence of childbirths was decreased throughout the 10-year follow-up for aggressive NHL. Children of NHL patients were more likely to be born following assisted reproductive technology than those of comparators, except for male indolent lymphoma patients. In conclusion, fertility counselling is particularly important for patients with aggressive NHL.

Published
2023
Full Text
View/download PDF

11. A retrospective head‐to‐head comparison of the Lugano classification and PERCIST for FDG‐PET/CT response assessment in diffuse large B‐cell lymphoma.

Author

Nielsen, Nicklas B., Gerke, Oke, Nielsen, Anne L., Juul‐Jensen, Karen, Larsen, Thomas S., Møller, Michael B., and Hildebrandt, Malene G.

Subjects
DIFFUSE large B-cell lymphomas, END of treatment, PROGRESSION-free survival
Abstract

Background: Diffuse large B‐cell lymphoma (DLBCL) is the most common form of lymphoma. European guidelines recommend FDG‐PET/CT for staging and end of treatment (EOT) response assessment, mid‐treatment response assessment is optional. We compared the Lugano classification and PET Response Criteria In Solid Tumours (PERCIST) for FDG‐PET/CT response assessment in DLBCL head‐to‐head. Methods: We retrospectively included patients with DLBCL who underwent first‐line R‐CHOP(‐like) therapy (2013−2020). Interim and EOT FDG‐PET/CT response were reevaluated using the Lugano classification and PERCIST. Response was dichotomized into complete metabolic response (CMR) versus non‐CMR (interim and EOT) and responders versus nonresponders (interim only). The cutoff for nonresponse at interim was a Deauville score of 5 (DS5) with the Lugano classification and a partial metabolic response with ≤66% reduction in SULpeak using PERCIST (PERCIST66). Results: In multivariable Cox regression (N = 170), DS5 at interim, PERCIST66 at interim, non‐CMR at EOT with the Lugano classification and non‐CMR at EOT with PERCIST were predictive of progression‐free survival (PFS). The Lugano classification and PERCIST agreed perfectly at interim and EOT and with 98.4% for the identification of nonresponders at interim. The accuracy for predicting events within 2 years of diagnosis was 84.2% for DS‐5 at interim, 87.6% for PERCIST66 at interim, 86% for non‐CMR with the Lugano classification at EOT and 83.3% for non‐CMR with PERCIST at EOT. Conclusion: The Lugano classification and PERCIST were equally predictive of PFS. Nonresponse at interim and non‐CMR at EOT were predictive of poor PFS with comparable accuracy for predicting events within 2 years. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Author

Illerhaus, Gerald, primary, Ferreri, Andrés J.M., additional, Binder, Mascha, additional, Borchmann, Peter, additional, Hasenkamp, Justin, additional, Stilgenbauer, Stephan, additional, Roeth, Alexander, additional, Weber, Thomas, additional, Egerer, Gerlinde, additional, Ernst, Thomas, additional, Hertenstein, Bernd, additional, Lenz, Georg, additional, Kobbe, Guido, additional, Brunnberg, Uta, additional, Schmidt, Christian, additional, Kneba, Michael, additional, Dreyling, Martin, additional, Möhle, Robert, additional, Panse, Jens, additional, Heinicke, Thomas, additional, Schroll, Sebastian, additional, Larsen, Thomas S., additional, Salwender, Hans, additional, Naumann, Ralph, additional, Hess, Georg, additional, Thurner, Lorenz, additional, Pukrop, Tobias, additional, Keller, Ulrich, additional, Blystadt, Anne Kirsti, additional, Kroschinsky, Frank P., additional, Re, Francesca, additional, Pulczynski, Elisa, additional, Orsucci, Lorella, additional, Pospiech, Lisa, additional, Deckert, Martina, additional, Ponzoni, Maurilio, additional, Wendler, Julia, additional, Valk, Elke, additional, Calimeri, Teresa, additional, Kasenda, Benjamin, additional, Trepel, Martin, additional, Fricker, Heidi, additional, von Gottberg, Philipp, additional, Burger, Elvira, additional, Ihorst, Gabriele, additional, Grishina, Olga, additional, Hader, Claudia, additional, Zucca, Emanuele, additional, Finke, Jürgen, additional, and Schorb, Elisabeth, additional

Published
2022
Full Text
View/download PDF

15. Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Author

Leppa, Sirpa, primary, Jørgensen, Judit M., additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Beiske, Klaus, additional, Pedersen, Mette, additional, Drott, Kristina, additional, Pasanen, Annika, additional, Karihtala, Kristiina, additional, Mannisto, Susanna, additional, Meriranta, Leo, additional, Wold, Bente, additional, Brodtkorb, Marianne, additional, Fagerli, Unn Merete, additional, Larsen, Thomas S., additional, Munksgaard, Lars, additional, Sunela, Kaisa, additional, Fluge, Øystein, additional, Jyrkkio, Sirkku, additional, Brown, Peter de Nully, additional, and Holte, Harald, additional

Published
2022
Full Text
View/download PDF

17. Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway

Author

Entrop, Joshua P.P., primary, Weibull, Caroline E., additional, Smedby, Karin E., additional, Jakobsen, Lasse Hjort, additional, Oevlisen, Andreas K., additional, Glimelius, Ingrid, additional, Marklund, Anna, additional, Larsen, Thomas S., additional, Holte, Harald, additional, Fosså, Alexander, additional, Smeland, Knut B., additional, El-Galaly, Tarec Christoffer Christoffer, additional, and Eloranta, Sandra, additional

Published
2022
Full Text
View/download PDF

18. Is It Possible to Omit Bone Marrow Biopsy in Diagnostic Workup in Patients with Newly Diagnosed Primary CNS Lymphoma? a Retrospective Analysis in the PET/CT Era

Author

Jelicic, Jelena, primary, Lund Hansen, Dennis, additional, Sand Carlsen, Sarah, additional, Thorsgaard, Michael, additional, Hersby, Ditte, additional, Kannik, Karina, additional, Munksgaard, Amalie Emilie, additional, Larsen, Thomas S., additional, and Juul-Jensen, Karen, additional

Published
2022
Full Text
View/download PDF

19. Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study

Author

Bennedsen, Tine, primary, Simonsen, Mikkel, additional, Brown, Peter de Nully, additional, Clausen, Michael Roost, additional, Dessau-Arp, Andriette, additional, Jørgensen, Judit, additional, Larsen, Thomas S., additional, Poulsen, Christian Bjørn, additional, Jakobsen, Lasse Hjort, additional, and El-Galaly, Tarec Christoffer Christoffer, additional

Published
2022
Full Text
View/download PDF

20. Outcome after 3rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Author

Ludvigsen Al-Mashhadi, Ahmed, primary, Jakobsen, Lasse Hjort, additional, Brown, Peter de Nully, additional, Ortved Gang, Anne, additional, Thorsteinsson, Anne-Luise, additional, Rasoul, Kaziwa, additional, Melchior Heissmann, Judith, additional, Buch Tøstesen, Michael, additional, Nieman Christoffersen, Mette, additional, Jelicic, Jelena, additional, Bøgh Jørgensen, Jennifer, additional, Thomsen, Troels, additional, Dessau-Arp, Andriette, additional, Andersen, Andreas PH, additional, Frederiksen, Mikael, additional, Pedersen, Per Troellund, additional, Clausen, Michael Roost, additional, Jørgensen, Judit, additional, Poulsen, Christian Bjørn, additional, El-Galaly, Tarec Christoffer Christoffer, additional, and Larsen, Thomas S., additional

Published
2022
Full Text
View/download PDF

21. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Author

Illerhaus, Gerald, Farreri, Andres J. M., Binder, Mascha, Borchmann, Peter, Hasenkamp, Justin, Stilgenbauer, Stephan, Roeth, Alexander, Webern, Thomas, Egerer, Gerlinde, Ernst, Thomas, Hertenstein, Bernd, Lenz, Georg, Kobbe, Guido, Brunnberg, Uta, Schmidt, Christian, Kneba, Michael, Dreyling, Martin, Moehle, Robert, Panse, Jens, Heinicke, Thomas, Schroll, Sebastian, Larsen, Thomas S., Salwender, Hans, Naumann, Ralph, Hess, Georg, Thurner, Lorenz, Pukrop, Tobias, Keller, Ulrich, Blystadt, Anne Kirsti, Kroschinsky, Frank P., Re, Francesca, Pulczynski, Elisa, Orsucci, Lorella, Pospiech, Lisa, Deckert, Martina, Ponzoni, Maurilio, Wendler, Julia, Valk, Elke, Calimeri, Teresa, Kasenda, Benjamin, Trepel, Martin, Fricker, Heidi, von Gottberg, Philipp, Burger, Elvira, Ihorst, Gabriele, Grishina, Olga, Hader, Claudia, Zucca, Emanuele, Finke, Juergen, Schorb, Elisabeth, Illerhaus, Gerald, Farreri, Andres J. M., Binder, Mascha, Borchmann, Peter, Hasenkamp, Justin, Stilgenbauer, Stephan, Roeth, Alexander, Webern, Thomas, Egerer, Gerlinde, Ernst, Thomas, Hertenstein, Bernd, Lenz, Georg, Kobbe, Guido, Brunnberg, Uta, Schmidt, Christian, Kneba, Michael, Dreyling, Martin, Moehle, Robert, Panse, Jens, Heinicke, Thomas, Schroll, Sebastian, Larsen, Thomas S., Salwender, Hans, Naumann, Ralph, Hess, Georg, Thurner, Lorenz, Pukrop, Tobias, Keller, Ulrich, Blystadt, Anne Kirsti, Kroschinsky, Frank P., Re, Francesca, Pulczynski, Elisa, Orsucci, Lorella, Pospiech, Lisa, Deckert, Martina, Ponzoni, Maurilio, Wendler, Julia, Valk, Elke, Calimeri, Teresa, Kasenda, Benjamin, Trepel, Martin, Fricker, Heidi, von Gottberg, Philipp, Burger, Elvira, Ihorst, Gabriele, Grishina, Olga, Hader, Claudia, Zucca, Emanuele, Finke, Juergen, and Schorb, Elisabeth

Published
2022

23. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL:a phase 2, open-label trial

Author

Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell’Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie Laure, Manzke, Oliver, Munoz, Javier, Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell’Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie Laure, Manzke, Oliver, and Munoz, Javier

Abstract

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R2-CHOP) in newly diagnosed high-risk DLBCL. Patients received durvalumab 1125 mg every 21 days for 2–8 cycles + R-CHOP (non-activated B-cell [ABC] subtype) or R2-CHOP (ABC), then durvalumab consolidation (1500 mg every 28 days). Of 46 patients, 43 received R-CHOP and three R2-CHOP. All patients had the high-risk disease; 14 (30.4%) and eight (17.4%) had double- or triple-hit DLBCL, respectively. Following induction, 20/37 (54.1%) patients receiving durvalumab + R-CHOP achieved complete response (CR), and seven (18.9%) partial response (PR); 25 (67.6% [95% CI 50.2–82.0]) continued to consolidation and were progression-free at 12 months. Among efficacy-evaluable patients with double- or triple-hit DLBCL (n = 12), five achieved CR and five PR. Adverse events were generally consistent with R-CHOP. Correlative analyses did not identify conclusive biomarkers of response. Durvalumab + R-CHOP is feasible in DLBCL with no new safety signals, but the combination provided no greater benefit than R-CHOP.

Published
2022

24. Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

Author

Fjorden, Karin, Ekberg, Sara, Kuric, Nevzeta, Smedby, Karin E., Lagerlöf, Ingemar, Larsen, Thomas S., Jorgensen, Judit M., de Nully Brown, Peter, Jerkeman, Mats, Fjorden, Karin, Ekberg, Sara, Kuric, Nevzeta, Smedby, Karin E., Lagerlöf, Ingemar, Larsen, Thomas S., Jorgensen, Judit M., de Nully Brown, Peter, and Jerkeman, Mats

Abstract

n/a, Funding Agencies|Gilead SciencesGilead Sciences Funding Source: Medline

Published
2022
Full Text
View/download PDF

25. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Author

Nowakowski, Grzegorz S., primary, Willenbacher, Wolfgang, additional, Greil, Richard, additional, Larsen, Thomas S., additional, Patel, Krish, additional, Jäger, Ulrich, additional, Manges, Robert F., additional, Trümper, Lorenz, additional, Everaus, Hele, additional, Kalakonda, Nagesh, additional, Brown, Peter, additional, Jørgensen, Judit Meszaros, additional, Cunningham, David, additional, Dell’Aringa, Justine, additional, Fox, Brian, additional, Rubio, Neus Domper, additional, Kilavuz, Nurgul, additional, Casadebaig, Marie-Laure, additional, Manzke, Oliver, additional, and Munoz, Javier, additional

Published
2021
Full Text
View/download PDF

27. Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Author

Hutchings, Martin, Avigdor, Abraham, Sureda Balari, Anna Maria, Terol, Maria José, Bosch, Francesc, Corradini, Paolo, Larsen, Thomas S., Rueda Dominguez, Antonio, Skarbnik, Alan, Joergensen, Judit Mészáros, Lavie, David, Gurion, Ronit, Zinzani, Pier Luigi, Pinto, Antonio, Cordoba, Raul, Bottos, Alessia, Li, Donghang, Relf, James, Filézac De L'Étang, Audrey, Sellam, Gila, and Gritti, Giuseppe

Published
2023
Full Text
View/download PDF

28. Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Author

Knudsen, Trine Alma, Hansen, Dennis Lund, Ocias, Lukas Frans, Bjerrum, Ole, Brabrand, Mette, Christensen, Sarah Friis, Eickhardt-Dalbøge, Christina Schjellerup, Ellervik, Christina, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Larsen, Morten Kranker, Mourits-Andersen, Torben, Möller, Sören, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Sørensen, Anders Lindholm, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas S., and Hasselbalch, Hans C.

Published
2023
Full Text
View/download PDF

30. Sigma A recognition sites in the Bacillus subtilis genome

Author

Jarmer, Hanne, Larsen, Thomas S., Krogh, Anders, Saxild, Hans Henrik, Brunak, Soren, and Knudsen, Steen

Subjects
Bacillus subtilis -- Genetic aspects, RNA polymerases -- Genetic aspects, Promoters (Entertainment) -- Genetic aspects, Genomes -- Analysis, Biological sciences
Abstract

Research indicates that a sigma(sup)A RNA polymerase cofactor recognition site exhibiting an extended -10 motifs can be constructed at the transcription initiation site of rapA and rapB promoters of Bacillus subtilis genome.

Published
2001

32. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

Author

Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas S., Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trümper, Lorenz, Everaus, Hele, Kalakonda, Nagesh, Brown, Peter, Jørgensen, Judit Meszaros, Cunningham, David, Dell'Aringa, Justine, Fox, Brian, Rubio, Neus Domper, Kilavuz, Nurgul, Casadebaig, Marie-Laure, Manzke, Oliver, and Munoz, Javier

Abstract

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R2-CHOP) in newly diagnosed high-risk DLBCL. Patients received durvalumab 1125 mg every 21 days for 2–8 cycles + R-CHOP (non-activated B-cell [ABC] subtype) or R2-CHOP (ABC), then durvalumab consolidation (1500 mg every 28 days). Of 46 patients, 43 received R-CHOP and three R2-CHOP. All patients had the high-risk disease; 14 (30.4%) and eight (17.4%) had double- or triple-hit DLBCL, respectively. Following induction, 20/37 (54.1%) patients receiving durvalumab + R-CHOP achieved complete response (CR), and seven (18.9%) partial response (PR); 25 (67.6% [95% CI 50.2–82.0]) continued to consolidation and were progression-free at 12 months. Among efficacy-evaluable patients with double- or triple-hit DLBCL (n = 12), five achieved CR and five PR. Adverse events were generally consistent with R-CHOP. Correlative analyses did not identify conclusive biomarkers of response. Durvalumab + R-CHOP is feasible in DLBCL with no new safety signals, but the combination provided no greater benefit than R-CHOP. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms

Author

Pedersen, Rasmus K., Andersen, Morten, Knudsen, Trine A., Sajid, Zamra, Gudmand-Hoeyer, Johanne, Dam, Marc J.B., Skov, Vibe, Kjær, Lasse, Ellervik, Christina, Larsen, Thomas S., Hansen, Dennis, Pallisgaard, Niels, Hasselbalch, Hans C., Ottesen, Johnny T., Pedersen, Rasmus K., Andersen, Morten, Knudsen, Trine A., Sajid, Zamra, Gudmand-Hoeyer, Johanne, Dam, Marc J.B., Skov, Vibe, Kjær, Lasse, Ellervik, Christina, Larsen, Thomas S., Hansen, Dennis, Pallisgaard, Niels, Hasselbalch, Hans C., and Ottesen, Johnny T.

Abstract

Treatment with PEGylated interferon-alpha2 (IFN) of patients with essential thrombocythemia and polycythemia vera induces major molecular remissions with a reduction in the JAK2V617F allele burden to undetectable levels in a subset of patients. A favorable response to IFN has been argued to depend upon the tumor burden, implying that institution of treatment with IFN should be as early as possible after the diagnosis. However, evidence for this statement is not available. We present a thorough analysis of unique serial JAK2V617F measurements in 66 IFN-treated patients and in 6 untreated patients. Without IFN treatment, the JAK2V617F allele burden increased exponentially with a period of doubling of 1.4 year. During monotherapy with IFN, the JAK2V617F allele burden decreased mono- or bi-exponentially for 33 responders of which 28 patients satisfied both descriptions. Bi-exponential description improved the fits in 19 cases being associated with late JAK2V617F responses. The decay of the JAK2V617F allele burden during IFN treatment was estimated to have half-lives of 1.6 year for the monoexponential response and 1.0 year in the long term for the bi-exponential response. In conclusion, through data-driven analysis of the JAK2V617F allele burden, we provide novel information regarding the JAK2V617F kinetics during IFN-treatment, arguing for early intervention.

Published
2020

35. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT:a national population-based cohort study

Author

Husby, Simon, Favero, Francesco, Nielsen, Christian, Sørensen, Betina S, Bæch, John, Grell, Kathrine, Hansen, Jakob W, Rodriguez-Gonzalez, Francisco G, Haastrup, Eva K, Fischer-Nielsen, Anne, Andersen, Pernille, Arboe, Bente, Sækmose, Susanne G, Hansen, Per B, Christiansen, Ilse, Clasen-Linde, Erik, Meldgaard, Lene, Ebbesen, Lene H, Segel, Erik K, Josefsson, Pär, Thorsgaard, Michael, El-Galaly, Tarec C, Brown, Peter, Weischenfeldt, Joachim, Larsen, Thomas S, Grønbæk, Kirsten, Husby, Simon, Favero, Francesco, Nielsen, Christian, Sørensen, Betina S, Bæch, John, Grell, Kathrine, Hansen, Jakob W, Rodriguez-Gonzalez, Francisco G, Haastrup, Eva K, Fischer-Nielsen, Anne, Andersen, Pernille, Arboe, Bente, Sækmose, Susanne G, Hansen, Per B, Christiansen, Ilse, Clasen-Linde, Erik, Meldgaard, Lene, Ebbesen, Lene H, Segel, Erik K, Josefsson, Pär, Thorsgaard, Michael, El-Galaly, Tarec C, Brown, Peter, Weischenfeldt, Joachim, Larsen, Thomas S, and Grønbæk, Kirsten

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is suspected of being a risk factor for patients with cancer. This study aimed to assess the clinical consequences of CHIP in patients with lymphoma intended for high-dose chemotherapy and autologous stem-cell transplantation (ASCT) in a population-based setting. We identified 892 lymphoma patients who had undergone stem cell harvest at all transplant centers in Denmark. A total of 565 patients had an available harvest sample, which was analysed for CHIP by next-generation sequencing, and the median follow-up was 9.1 years. Of the patients who were intended for immediate ASCT, 25.5% (112/440) carried at least one CHIP mutation. In contrast to previous single-center studies CHIP was not associated with inferior overall survival (OS) in multivariate analyses. However, patients with mutations in genes of the DNA repair pathway (PPM1D, TP53, RAD21, BRCC3) had a significant inferior OS (HR after 1 year of follow-up 2.79, 95% confidence interval 1.71-4.56; p < 0.0001), which also was evident in multivariate analysis (p = 0.00067). These patients had also increased rates of therapy-related leukemia and admission to intensive care. Furthermore, in patients who did not undergo immediate ASCT, a significant inferior OS of individuals with DNA repair mutations was also identified (p = 0.003).

Published
2020

37. Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms

Author

Pedersen, Rasmus K., primary, Andersen, Morten, additional, Knudsen, Trine A., additional, Sajid, Zamra, additional, Gudmand‐Hoeyer, Johanne, additional, Dam, Marc J. B., additional, Skov, Vibe, additional, Kjær, Lasse, additional, Ellervik, Christina, additional, Larsen, Thomas S., additional, Hansen, Dennis, additional, Pallisgaard, Niels, additional, Hasselbalch, Hans C., additional, and Ottesen, Johnny T., additional

Published
2020
Full Text
View/download PDF

38. Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy

Author

Clausen, Michael R, primary, Maurer, Matthew J, additional, Ulrichsen, Sinna Pilgaard, additional, Larsen, Thomas S, additional, Himmelstrup, Bodil, additional, Rønnov-Jessen, Dorthe, additional, Link, Brian K, additional, Feldman, Andrew L, additional, Slager, Susan L, additional, Nowakowski, Grzegorz S, additional, Thompson, Carrie A, additional, Pedersen, Per Trøllund, additional, Madsen, Jakob, additional, Pedersen, Robert S, additional, Gørløv, Jette Sønderskov, additional, Cerhan, James R, additional, Nørgaard, Mette, additional, and D’Amore, Francesco, additional

Published
2019
Full Text
View/download PDF

39. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Author

Biccler, Jorne L., primary, Savage, Kerry J., additional, Brown, Peter D.N., additional, Jørgensen, Judit, additional, Larsen, Thomas S., additional, Poulsen, Christian B., additional, Stoltenberg, Danny, additional, Sehn, Laurie H., additional, Scott, David W., additional, Gerrie, Alina S., additional, Jakobsen, Lasse H., additional, Bøgsted, Martin, additional, El-Galaly, Tarec C., additional, and Villa, Diego, additional

Published
2019
Full Text
View/download PDF

40. Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy

Author

Clausen,Michael R, Maurer,Matthew J, Ulrichsen,Sinna Pilgaard, Larsen,Thomas S, Himmelstrup,Bodil, Rønnov-Jessen,Dorthe, Link,Brian K, Feldman,Andrew L, Slager,Susan L, Nowakowski,Grzegorz S, Thompson,Carrie A, Pedersen,Per Trøllund, Madsen,Jakob, Pedersen,Robert S, Gørløv,Jette Sønderskov, Cerhan,James R, Nørgaard,Mette, D’Amore,Francesco, Clausen,Michael R, Maurer,Matthew J, Ulrichsen,Sinna Pilgaard, Larsen,Thomas S, Himmelstrup,Bodil, Rønnov-Jessen,Dorthe, Link,Brian K, Feldman,Andrew L, Slager,Susan L, Nowakowski,Grzegorz S, Thompson,Carrie A, Pedersen,Per Trøllund, Madsen,Jakob, Pedersen,Robert S, Gørløv,Jette Sønderskov, Cerhan,James R, Nørgaard,Mette, and D’Amore,Francesco

Abstract

Michael R Clausen,1 Matthew J Maurer,2 Sinna Pilgaard Ulrichsen,3 Thomas S Larsen,4 Bodil Himmelstrup,5 Dorthe Rønnov-Jessen,6 Brian K Link,7 Andrew L Feldman,8 Susan L Slager,2 Grzegorz S Nowakowski,9 Carrie A Thompson,9 Per Trøllund Pedersen,10 Jakob Madsen,11 Robert S Pedersen,12 Jette Sønderskov Gørløv,13 James R Cerhan,2 Mette Nørgaard,1 Francesco D’Amore1 1Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 4Department of Hematology, Odense University Hospital, Odense, Denmark; 5Department of Hematology, Zealand University Hospital, Roskilde, Denmark; 6Department of Hematology, Sygehus Lillebaelt, Vejle, Denmark; 7Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; 8Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 9Department of Medicine, Mayo Clinic, Rochester, MN, USA; 10Department of Hematology, Sydvestjysk Sygehus, Esbjerg, Denmark; 11Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; 12Department of Hematology, Hospitalsenheden Vest, Holstebro, Denmark; 13Department of Hematology, Rigshospitalet, Copenhagen, DenmarkCorrespondence: Michael R ClausenDepartment of Hematology, Aarhus University Hospital, Palle Juul-Jensens Blvd 35, Aarhus, DenmarkEmail mrc@clin.au.dkBackground: Hemoglobin (Hgb) concentration at diagnosis is associated with outcome in cancer. In a recently reported simplified 3-factor prognostic score in Hodgkin lymphoma, Hgb, along with age and clinical stage, outperformed the classical International Prognostic Score with seven parameters.Methods: In the present study, we investigated if pretherapeutic Hgb concentration added prognostic information to the NCCN-IPI in diffuse large B-cell lymphoma. We included patients fr

Published
2019

41. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Author

Biccler, Jorne L., Savage, Kerry J., Brown, Peter D.N., Jørgensen, Judit, Larsen, Thomas S., Poulsen, Christian B., Stoltenberg, Danny, Sehn, Laurie H., Scott, David W., Gerrie, Alina S., Jakobsen, Lasse H., Bøgsted, Martin, El-galaly, Tarec C., Villa, Diego, Biccler, Jorne L., Savage, Kerry J., Brown, Peter D.N., Jørgensen, Judit, Larsen, Thomas S., Poulsen, Christian B., Stoltenberg, Danny, Sehn, Laurie H., Scott, David W., Gerrie, Alina S., Jakobsen, Lasse H., Bøgsted, Martin, El-galaly, Tarec C., and Villa, Diego

Published
2019

42. Improving bench scale design for polymerisation of green CO2-polymers

Author

Larsen, Thomas S., Sætre, Kai Arne, Ronasi, Sara, Haugen, Hildegunn H., and Moldestad, Britt Margrethe Emilie

Abstract

Plastic has become the most common material since the beginning of the 20th century and has become almost indispensable due to its durability, light weight and low costs. However, some of the characteristics also make the plastic problematic when it comes to the end of its life phase. Norner Research AS, a polymer research institute performing extensive independent or funded research in the plastic value chain from process technology to final product and application, has during the last ten years been active in developing biodegradable green plastic that can replace up to 40% of the fossil raw materials with industrial captured CO2. The green plastic, poly(propylene carbonate) (PPC), is produced by reacting propylene oxide (PO) with CO2. The aim of this paper is to study the effect of static mixer on production of PPC and improve the catalytic process by reducing the reaction time and increasing the yield. The process includes multiphase gas-liquid flow, and good mixing is one of the key factors to succeed in improving the process. The flow behavior of the components in the multi-phase bench scale reactor is studied in order to investigate the potential of reducing the reaction time by using static mixers to increase mass transfer. A static mixer is a device for the continuous mixing of fluids, and can be used to mix liquids, gases or to mix a gas into a liquid. The energy needed for mixing comes from a loss in pressure as the fluids flow through the static mixer. Computational fluid dynamic (CFD) is an important tool in order to simulate and optimize the polymerization process. In this study, the CFD software Ansys/Fluent is used to investigate the multiphase flow through the static mixer. The static mixer is simulated to study the effect on the gas-liquid mixing. The simulations were performed with mixtures of 17% and 34% PPC in PO under CO2 pressure. The simulations showed that the required number of mixing elements (L) to obtain a uniform mixing of CO2, PO and PPC in the liquid phase is estimated to be 6.5L for the 17% PPC case and 5.25L for the 34% PPC case. Consequently, using more than the required number of mixing elements would increase the pressure drop without increasing the mixing. It was observed that the required mixer length decreased when the composition of PPC in the inlet liquid phase was increased from 17% to 34%. Improving bench scale design for polymerisation of green CO2-polymers

Published
2018

45. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma

Author

Bech, Rie S., primary, Nielsen, Kasper L., additional, Larsen, Thomas S., additional, Bentzen, Hans H., additional, Lynggaard, Line S., additional, Do, Trung H., additional, Braendstrup, Peter, additional, Brady, Jessica, additional, Mikhaeel, N. George, additional, Dybkaer, Karen, additional, Johnsen, Hans E., additional, Jensen, Paw, additional, Bøgsted, Martin, additional, and El-Galaly, Tarec C., additional

Published
2017
Full Text
View/download PDF

46. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma:An international multicenter study of 1532 patients treated with chemoimmunotherapy

Author

El-Galaly, Tarec Christoffer, Villa, Diego, Michaelsen, Thomas Yssing, Hutchings, Martin, Mikhaeel, Nabegh George, Savage, Kerry J., Sehn, Laurie H., Barrington, Sally, Hansen, Jakob W., Smith, Daniel, Rady, Kirsty, Mylam, Karen J., Larsen, Thomas S., Holmberg, Staffan, Juul, Maja B., Cordua, Sabrina, Clausen, Michael R., Jensen, Kristina B., Johnsen, Hans E., Seymour, John F., Connors, Joseph M., de Nully Brown, Peter, Bøgsted, Martin, Cheah, Chan Y., El-Galaly, Tarec Christoffer, Villa, Diego, Michaelsen, Thomas Yssing, Hutchings, Martin, Mikhaeel, Nabegh George, Savage, Kerry J., Sehn, Laurie H., Barrington, Sally, Hansen, Jakob W., Smith, Daniel, Rady, Kirsty, Mylam, Karen J., Larsen, Thomas S., Holmberg, Staffan, Juul, Maja B., Cordua, Sabrina, Clausen, Michael R., Jensen, Kristina B., Johnsen, Hans E., Seymour, John F., Connors, Joseph M., de Nully Brown, Peter, Bøgsted, Martin, and Cheah, Chan Y.

Abstract

Purpose Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients at greatest risk, but the optimal model is unknown. Methods We retrospectively analysed patients with diffuse large B-cell lymphoma diagnosed between 2001 and 2013, staged with PET/CT and treated with R-CHOP(-like) regimens. Baseline clinicopathologic characteristics, treatments, and outcome data were collected from clinical databases and medical files. We evaluated the association between candidate prognostic factors and modelled different risk models for predicting SCNS. Results Of 1532 patients, 62 (4%) subsequently developed SCNS. By multivariate analysis, disease stage III/IV, elevated serum LDH, kidney/adrenal and uterine/testicular involvement were independently associated with SCNS. There was a strong correlation between absolute number of extranodal sites and risk of SCNS; the 144 patients (9%) with >2 extranodal sites had a 3-year cumulative incidence of SCNS of 15.2% (95% confidence interval [CI] 9.2–21.2%) compared with 2.6% (95% CI 1.7–3.5) among those with ≤2 sites (P < 0.001). The 3-year cumulative risks of SCNS for CNS-IPI defined risk groups were 11.2%, 3.1% and 0.4% for high-, intermediate- and low-risk patients, respectively. All risk models analysed had high negative predictive values, but only modest positive predictive values. Conclusions Patients with >2 extranodal sites or high-risk disease according to the CNS-IPI should be considered for baseline CNS staging. Clinical risk prediction models suffer from limited positive predictive ability, highlighting the need for more sensitive biomarkers to identify patients at highest risk of this devastating complication.

Published
2017

47. An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma

Author

El-Galaly, Tarec Christoffer, primary, Cheah, Chan Yoon, additional, Bendtsen, Mette Dahl, additional, Thanarasjasingam, Gita, additional, Kansara, Roopesh, additional, Savage, Kerry J, additional, Connors, Joseph M., additional, Goldschmidt, Neta, additional, Shaulov, Adir, additional, Farooq, Umar, additional, Sehn, Laurie H, additional, Dann, Eldad J, additional, Thompson, Carrie A, additional, Inbar, Tsofia, additional, Link, Brian K, additional, Maurer, Matthew J, additional, Gade, Inger Lise, additional, Juul, Maja Bech, additional, Hansen, Jakob W, additional, Holmberg, Staffan, additional, Larsen, Thomas S, additional, Opat, Stephen, additional, Mikhaeel, N George, additional, Seymour, John F, additional, Clausen, Michael Roost, additional, Smith, Daniel, additional, Gilbertson, Michael, additional, Nowakowski, Grzegorz S, additional, Cordua, Sabrina, additional, Hutchings, Martin, additional, and Villa, Diego, additional

Published
2016
Full Text
View/download PDF

48. Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Author

Leppa, Sirpa, primary, Joergensen, Judit, additional, Tierens, Anne, additional, Østlie, Ingunn, additional, Fagerli, Unn Merete, additional, Brown, Peter de Nully, additional, Larsen, Thomas S, additional, Mannisto, Susanna, additional, Munksgaard, Lars, additional, Maisenhölder, Martin, additional, Vasala, Kaija, additional, Meyer, Peter, additional, Jerkeman, Mats, additional, Bjorkholm, Magnus, additional, Fluge, Oystein, additional, Jyrkkio, Sirkku, additional, Ralfkiaer, Elisabeth, additional, Spetalen, Signe, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, and Holte, Harald, additional

Published
2016
Full Text
View/download PDF

50. Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B‐cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement

Author

El‐Galaly, Tarec Christoffer, primary, Cheah, Chan Y., additional, Hutchings, Martin, additional, Mikhaeel, Nabegh George, additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Barrington, Sally, additional, Hansen, Jakob W., additional, Poulsen, Mette Ø., additional, Smith, Daniel, additional, Rady, Kirsty, additional, Mylam, Karen J., additional, Larsen, Thomas S., additional, Holmberg, Staffan, additional, Juul, Maja B., additional, Cordua, Sabrina, additional, Clausen, Michael R., additional, Jensen, Kristina B., additional, Bøgsted, Martin, additional, Johnsen, Hans E., additional, Seymour, John F., additional, Connors, Joseph M., additional, Brown, Peter d. N., additional, and Villa, Diego, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results